Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

RETRACTED ARTICLE: Association of GSTT1 gene polymorphisms with the risk of prostate cancer: an updating meta-analysis

Authors: Jihong Wang, Yuemin Xu, Qiang Fu, Jianjun Yu, Zhong Chen, Zhangshun Liu, Chao Li, Hui Guo, Mingkai Xie

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

It has been demonstrated that the glutathione S-transferase (GST) superfamily helps remove carcinogens from the body and thus might be associated with prostate cancer risk. In recent years, GSTT1 polymorphism has been extensively studied as a potential prostate cancer risk factor; however, the results are inconsistent. To investigate the association between GSTT1 and prostate cancer, we conducted a meta-analysis of 33 studies with 6,697 prostate patients and 7,643 controls. For GSTM1 null versus present genotype, the random effects odds ratio was 0.98 (95 % confidence interval (CI) 0.83–1.16) based on a wide population. Subgroup analyses in the different ethnic groups and different controls were performed. The OR was 1.01 (95 % CI 0.86–1.19) in Caucasians, 1.01 (95 % CI 0.70–1.47) in Asians, and 0.77 (95 % CI 0.42–1.42) in Africans. The OR was 0.98 (95 % CI 0.82–1.16) in non-benign prostate hyperplasia (BPH) controls and 1.09 (95 % CI 0.66–1.79) in BPH controls. In conclusion, our present meta-analysis demonstrates that there is no association between GSTT1 polymorphism and prostate cancer, even in the sub-analysis concerning different races and control sources. The direction of further research should focus not only on the simple relationship of GSTT1 and prostate cancer but also on gene–environment interaction and distinctions of different GSTs.
Literature
1.
2.
Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat Res. 1999;436:227–61.CrossRefPubMed
3.
Ryberg D, Skaug V, Hewer A, Phillips DH, Harries LW, Wolf CR, Ogreid D, Ulvik A, Vu P, Haugen A. Genotypes of glutathione transferase m1 and p1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis. 1997;18:1285–9.CrossRefPubMed
4.
Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445–600.CrossRefPubMed
5.
Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J. 1994;300(Pt 1):271–6.CrossRefPubMedPubMedCentral
6.
Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1997;6:733–43.PubMed
7.
Ntais C, Polycarpou A, Ioannidis JP. Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005;14:176–81.PubMed
8.
Mo Z, Gao Y, Cao Y, Gao F, Jian L. An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a huge review. Prostate. 2009;69:662–88.CrossRefPubMed
9.
10.
Autrup JL, Thomassen LH, Olsen JH, Wolf H, Autrup H. Glutathione S-transferases as risk factors in prostate cancer. Eur J Cancer Prev. 1999;8:525–32.CrossRefPubMed
11.
Rebbeck TR, Walker AH, Jaffe JM, White DL, Wein AJ, Malkowicz SB. Glutathione S-transferase-mu (GSTM1) and -theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:283–7.PubMed
12.
Steinhoff C, Franke KH, Golka K, Thier R, Romer HC, Rotzel C, Ackermann R, Schulz WA. Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol. 2000;74:521–6.CrossRefPubMed
13.
Gsur A, Haidinger G, Hinteregger S, Bernhofer G, Schatzl G, Madersbacher S, Marberger M, Vutuc C, Micksche M. Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer. 2001;95:152–5.CrossRefPubMed
14.
Kote-Jarai Z, Easton D, Edwards SM, Jefferies S, Durocher F, Jackson RA, Singh R, Ardern-Jones A, Murkin A, Dearnaley DP, Shearer R, Kirby R, Houlston R, Eeles R. Collaborators CBUFPCS: relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics. 2001;11:325–30.CrossRefPubMed
15.
Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, Katoh T, Kamataki T, Kawamura J, Yatani R, Shiraishi T. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the japanese population. Cancer Lett. 2001;165:171–7.CrossRefPubMed
16.
Beer TM, Evans AJ, Hough KM, Lowe BA, McWilliams JE, Henner WD. Polymorphisms of GSTP1 and related genes and prostate cancer risk. Prostate Cancer Prostatic Dis. 2002;5:22–7.CrossRefPubMed
17.
Kidd LC, Woodson K, Taylor PR, Albanes D, Virtamo J, Tangrea JA. Polymorphisms in glutathione-S-transferase genes (GST-M1, GST-T1 and GST-P1) and susceptibility to prostate cancer among male smokers of the atbc cancer prevention study. Eur J Cancer Prev. 2003;12:317–20.CrossRefPubMed
18.
Nakazato H, Suzuki K, Matsui H, Koike H, Okugi H, Ohtake N, Takei T, Nakata S, Hasumi M, Ito K, Kurokawa K, Yamanaka H. Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population. Anticancer Res. 2003;23:2897–902.PubMed
19.
Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprini D, Chu W, Ho M, Sweet J, Evans A, Toi A, Pollak M, Narod SA. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:1429–37.PubMed
20.
Joseph MA, Moysich KB, Freudenheim JL, Shields PG, Bowman ED, Zhang Y, Marshall JR, Ambrosone CB. Cruciferous vegetables, genetic polymorphisms in glutathione S-transferases M1 and T1, and prostate cancer risk. Nutr Cancer. 2004;50:206–13.CrossRefPubMed
21.
Medeiros R, Vasconcelos A, Costa S, Pinto D, Ferreira P, Lobo F, Morais A, Oliveira J, Lopes C. Metabolic susceptibility genes and prostate cancer risk in a southern european population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate. 2004;58:414–20.CrossRefPubMed
22.
Mittal RD, Srivastava DS, Mandhani A, Kumar A, Mittal B. Polymorphism of GSTM1 and GSTT1 genes in prostate cancer: a study from north india. Indian J Cancer. 2004;41:115–9.PubMed
23.
Caceres DD, Iturrieta J, Acevedo C, Huidobro C, Varela N, Quinones L. Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: exploring some gene–gene and gene–environment interactions. Eur J Epidemiol. 2005;20:79–88.CrossRefPubMed
24.
Komiya Y, Tsukino H, Nakao H, Kuroda Y, Imai H, Katoh T. Human glutathione S-transferase A1, T1, M1, and P1 polymorphisms and susceptibility to prostate cancer in the Japanese population. J Cancer Res Clin Oncol. 2005;131:238–42.CrossRefPubMed
25.
Srivastava DS, Mandhani A, Mittal B, Mittal RD. Genetic polymorphism of glutathione S-transferase genes (GSTM1, GSTT1 and GSTP1) and susceptibility to prostate cancer in northern India. BJU Int. 2005;95:170–3.CrossRefPubMed
26.
Agalliu I, Langeberg WJ, Lampe JW, Salinas CA, Stanford JL. Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men. Prostate. 2006;66:146–56.CrossRefPubMed
27.
Mittal RD, Mishra DK, Mandhani A. Evaluating polymorphic status of glutathione-S-transferase genes in blood and tissue samples of prostate cancer patients. Asian Pac J Cancer Prev. 2006;7:444–6.PubMed
28.
Silig Y, Pinarbasi H, Gunes S, Ayan S, Bagci H, Cetinkaya O. Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in turkish population. Cancer Invest. 2006;24:41–5.CrossRefPubMed
29.
Yang J, Wu HF, Zhang W, Gu M, Hua LX, Sui YG, Zhang ZD, Zhou JW, Wang XR, Zou C, Qian LX. Polymorphisms of metabolic enzyme genes, living habits and prostate cancer susceptibility. Front Biosci. 2006;11:2052–60.PubMed
30.
Mallick S, Romana M, Blanchet P, Multigner L. GSTM1 and GSTT1 polymorphisms and the risk of prostate cancer in a caribbean population of african descent. Urology. 2007;69:1165–9.CrossRefPubMed
31.
Lima Jr MM, Oliveira MN, Granja F, Trindade AC, De Castro Santos LE, Ward LS. Lack of association of GSTT1, GSTM1, GSTO1, GSTP1 and CYP1A1 polymorphisms for susceptibility and outcome in brazilian prostate cancer patients. Folia Biol (Praha). 2008;54:102–8.
32.
Lavender NA, Benford ML, VanCleave TT, Brock GN, Kittles RA, Moore JH, Hein DW, Kidd LC. Examination of polymorphic glutathione S-transferase (GST) genes, tobacco smoking and prostate cancer risk among men of african descent: a case–control study. BMC Cancer. 2009;9:397.CrossRefPubMedPubMedCentral
33.
Sivonova M, Waczulikova I, Dobrota D, Matakova T, Hatok J, Racay P, Kliment J. Polymorphisms of glutathione-S-transferase M1, T1, P1 and the risk of prostate cancer: a case–control study. J Exp Clin Cancer Res. 2009;28:32.CrossRefPubMedPubMedCentral
34.
Souiden Y, Mahdouani M, Chaieb K, Elkamel R, Mahdouani K. Polymorphisms of glutathione-S-transferase M1 and T1 and prostate cancer risk in a Tunisian population. Cancer Epidemiol. 2010;34:598–603.CrossRefPubMed
35.
Ashtiani ZO, Hasheminasab SM, Ayati M, Goulian BS, Modarressi MH. Are GSTM1, GSTT1 and CAG repeat length of androgen receptor gene polymorphisms associated with risk of prostate cancer in iranian patients? Pathol Oncol Res. 2011;17:269–75.CrossRefPubMed
36.
Kumar V, Yadav CS, Datta SK, Singh S, Ahmed RS, Goel S, Gupta S, Mustafa M, Grover RK, Banerjee BD. Association of GSTM1 and GSTT1 polymorphism with lipid peroxidation in benign prostate hyperplasia and prostate cancer: a pilot study. Dis Markers. 2011;30:163–9.CrossRefPubMedPubMedCentral
37.
Kwon DD, Lee JW, Han DY, Seo IY, Park SC, Jeong HJ, Yang YS, Chae SC, Na KS, Mo KJ, Kim JJ, Rim JS. Relationship between the glutathione-S-transferase P1, M1, and T1 genotypes and prostate cancer risk in Korean subjects. Korean J Urol. 2011;52:247–52.CrossRefPubMedPubMedCentral
38.
Rodrigues IS, Kuasne H, Losi-Guembarovski R, Fuganti PE, Gregorio EP, Kishima MO, Ito K, de Freitas Rodrigues MA, de Syllos Colus IM. Evaluation of the influence of polymorphic variants CYP1A1 2B, CYP1B1 2, CYP3A4 1B, GSTM1 0, and GSTT1 0 in prostate cancer. Urol Oncol. 2011;29:654–63.CrossRefPubMed
39.
Safarinejad MR, Shafiei N, Safarinejad SH. Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, GSTP1) and prostate cancer: a case–control study in Tehran, Iran. Prostate Cancer Prostatic Dis. 2011;14:105–13.CrossRefPubMed
40.
Thakur H, Gupta L, Sobti RC, Janmeja AK, Seth A, Singh SK. Association of GSTM1T1 genes with copd and prostate cancer in north Indian population. Mol Biol Rep. 2011;38:1733–9.CrossRefPubMed
41.
Catsburg C, Joshi AD, Corral R, Lewinger JP, Koo J, John EM, Ingles SA, Stern MC. Polymorphisms in carcinogen metabolism enzymes, fish intake, and risk of prostate cancer. Carcinogenesis. 2012;33:1352–9.CrossRefPubMedPubMedCentral
42.
Choubey VK, Sankhwar SN, Tewari R, Sankhwar P, Singh BP, Rajender S: Null genotypes at the GSTM1 and GSTT1 genes and the risk of benign prostatic hyperplasia: a case–control study and a meta-analysis. Prostate. 2013;73:146–52.CrossRefPubMed
43.
44.
Fost U, Hallier E, Ottenwalder H, Bolt HM, Peter H. Distribution of ethylene oxide in human blood and its implications for biomonitoring. Hum Exp Toxicol. 1991;10:25–31.CrossRefPubMed
45.
Hallier E, Deutschmann S, Reichel C, Bolt HM, Peter H. A comparative investigation of the metabolism of methyl bromide and methyl iodide in human erythrocytes. Int Arch Occup Environ Health. 1990;62:221–5.CrossRefPubMed
46.
Hallier E, Schroder KR, Asmuth K, Dommermuth A, Aust B, Goergens HW. Metabolism of dichloromethane (methylene chloride) to formaldehyde in human erythrocytes: influence of polymorphism of glutathione transferase theta (GST T1-1). Arch Toxicol. 1994;68:423–7.CrossRefPubMed
47.
Guengerich FP, Thier R, Persmark M, Taylor JB, Pemble SE, Ketterer B. Conjugation of carcinogens by theta class glutathione S-transferases: mechanisms and relevance to variations in human risk. Pharmacogenetics. 1995;5 Spec No:S103–7.CrossRefPubMed
48.
Wiencke JK, Pemble S, Ketterer B, Kelsey KT. Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev. 1995;4:253–9.PubMed
49.
Taioli E, Flores-Obando RE, Agalliu I, Blanchet P, Bunker CH, Ferrell RE, Jackson M, Kidd LC, Kolb S, Lavender NA, McFarlane-Anderson N, Morrison SS, Multigner L, Ostrande EA, Park JY, Patrick AL, Rebbeck TR, Romana M, Stanford JL, Ukoli F, Vancleave TT, Zeigler-Johnson CM, Mutetwa B, Ragin C. Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis. 2011;32:1361–5.CrossRefPubMedPubMedCentral
50.
51.
Wei B, Xu Z, Zhou Y, Ruan J, Cheng H, Xi B, Zhu M, Jin K, Zhou D, Hu Q, Wang Q, Wang Z, Yan Z, Xuan F, Huang X, Zhang J, Zhou H. Association of gstm1 null allele with prostate cancer risk: evidence from 36 case–control studies. PLoS One. 2012;7:e46982.CrossRefPubMedPubMedCentral
52.
53.
Zuccolo L, Lewis SJ, Donovan JL, Hamdy FC, Neal DE, Smith GD. Alcohol consumption and PSA-detected prostate cancer risk—a case–control nested in the protect study. Int J Cancer. 2013;132:2176–85.CrossRefPubMed
54.
Nock NL, Tang D, Rundle A, Neslund-Dudas C, Savera AT, Bock CH, Monaghan KG, Koprowski A, Mitrache N, Yang JJ, Rybicki BA. Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race. Cancer Epidemiol Biomarkers Prev. 2007;16:1236–45.CrossRefPubMedPubMedCentral
55.
Mannervik B, Awasthi YC, Board PG, Hayes JD, Di Ilio C, Ketterer B, Listowsky I, Morgenstern R, Muramatsu M, Pearson WR, et al. Nomenclature for human glutathione transferases. Biochem J. 1992;282(Pt 1):305–6.CrossRefPubMedPubMedCentral
56.
Widersten M, Pearson WR, Engstrom A, Mannervik B. Heterologous expression of the allelic variant mu-class glutathione transferases mu and psi. Biochem J. 1991;276(Pt 2):519–24.CrossRefPubMedPubMedCentral
57.
Lof A, Johanson G, Rannug A, Warholm M. Glutathione transferase T1 phenotype affects the toxicokinetics of inhaled methyl chloride in human volunteers. Pharmacogenetics. 2000;10:645–53.CrossRefPubMed
58.
Thier R, Lewalter J, Kempkes M, Selinski S, Bruning T, Bolt HM. Haemoglobin adducts of acrylonitrile and ethylene oxide in acrylonitrile workers, dependent on polymorphisms of the glutathione transferases GSTT1 and GSTM1. Arch Toxicol. 1999;73:197–202.CrossRefPubMed
59.
Seidegard J, Pero RW, Miller DG, Beattie EJ. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis. 1986;7:751–3.CrossRefPubMed
60.
Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol. 1993;14:77–87.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Association of GSTT1 gene polymorphisms with the risk of prostate cancer: an updating meta-analysis
Authors
Jihong Wang
Yuemin Xu
Qiang Fu
Jianjun Yu
Zhong Chen
Zhangshun Liu
Chao Li
Hui Guo
Mingkai Xie
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0640-8

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue

Research Article

CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer

Research Article

MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells

Research Article

Effect of lomeguatrib–temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells

Research Article

Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells

Research Article

Cell growth inhibition in HPV 18 positive uveal melanoma cells by E6/E7 siRNA

Research Article

Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits